Anti-Human Lymphotoxin beta R/TNFRSF3 Reference Antibody (CBE-11, RUO) (HW495016)

Name: Anti-Human Lymphotoxin beta R/TNFRSF3 Reference Antibody (CBE-11, RUO)
Brand: abinScience
SKU: HW495016
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW495016
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1-kappa
Clone ID	CBE-11
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Tumor necrosis factor receptor superfamily member 3, Lymphotoxin-beta receptor, Tumor necrosis factor C receptor, Tumor necrosis factor receptor 2-related protein, Tumor necrosis factor receptor type III, TNF-RIII, TNFR-III, LTBR, D12S370, TNFCR, TNFR3, TNFRSF3
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P36941
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	hCBE-11, CBE-11, HCBE11, CBE11, CBE11
Background	Tumor necrosis factor receptor superfamily member 3 (LTBR/TNFR-III) is a ~46 kDa protein. Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. Activates NF-kappa-B signaling pathway upon stimulation with lymphotoxin (LTA(1)-LTB(2)). Promotes apoptosis via TRAF3 and TRAF5. May play a role in the development of lymphoid organs. 1. Sudhamsu, J. et al. (2013) Proceedings of the National Academy of Sciences of the United States of America 110, 19896-901. PMID: 24248355
References	1. Lukashev M, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006 Oct 1;66(19):9617-24. [HW495016]
Note	For research use only. Not suitable for clinical or therapeutic use.